Moxetumomab Pasudotox: First Global Approval

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

(2018) Robert J. Kreitman et al.   BLOOD

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

(2018) Robert J. Kreitman et al.   LEUKEMIA

Efficacy and safety of moxetumomab pasudotox (moxe) in adult patients (pts) with relapsed/refractory hairy cell leukemia (HCL) in relation to drug exposure, baseline disease burden, and immunogenicity.

(2018) Denison Kuruvilla et al.   JOURNAL OF CLINICAL ONCOLOGY

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

(2016) Michael R. Grever et al.   BLOOD

Hairy cell leukemia: Past, present and future

(2015) Bartlomiej M. Getta et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

(2012) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

(2011) R. J. Kreitman et al.   CLINICAL CANCER RESEARCH

CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies

(2009) R. F. Alderson et al.   CLINICAL CANCER RESEARCH